GlobeNewswire

VIRBAC: Revenue grew +6.8% at constant exchange rates and scope at the end of September 2020 (+5.6% at constant rates) thanks to solid third quarter performance

Share


KEY FIGURES
Revenue
Year-to-date September 2020


€713.9 million
Total growth


+2.4%
(+3.3% excl. Sentinel)
Growth at constant exchange rates


+5.6% 
Growth at constant exchange rates and scope 1


+6.8% including

companion animals +3.6% (+6.1% excluding Sentinel)
food-producing animals+8.2%





1
Growth at constant exchange rates and scope is the organic growth of sales, excluding the impact of exchange rate changes, by calculating the indicator for the financial year in question and that for the previous financial year on the basis of identical exchange rates (the exchange rate used is that in effect for the previous financial year), and excluding the impact of changes in scope, by calculating the indicator for the financial year in question on the basis of the scope of consolidation for the previous financial year, and by excluding sales of Sentinel for the two financial years in question.


Quarterly consolidated revenue

Revenue reached €235.6 million in the third quarter, an increase of +0.9% compared to the same period in 2019. At constant exchange rates, the third quarter registered a solid performance of +6.8% (+11.1% excluding Sentinel), as the strong depreciation of certain currencies, particularly the Brazilian real, Mexican peso, South African rand and the rupee, weighed heavily on performance.

Excluding the impact of the divestment of Sentinel in the United States, all regions are experiencing growth against the same period in 2019. This growth was led by the Asia-Pacific region and Europe, thanks to excellent performances by India and China, which posted strong double-digit growth over the period. France, Benelux, Spain and Italy thus reabsorbed some of the lag observed in the first half of the year. The United States posted double-digit growth excluding Sentinel, thanks in particular to products from the specialty range. Latin America achieved quarterly growth mainly driven by Mexico and Brazil, while Chile was down. In terms of species, the food-producing animals segment saw double-digit growth, driven in particular by the ruminant business and the industrial sector (swine and poultry). The companion animals segment is also growing sharply, despite lower vaccine sales following supply disruptions related to the shutdown of our global dog and cat vaccine production site in Carros, France.

Cumulative consolidated revenue at the end of September
Over the first half of the year as a whole, revenue amounted to €713.9 million compared to €697.3 million for the same period in 2019, representing an overall increase of +2.4% (+3.3% excluding Sentinel). Revenue increased by +5.6% (+6.8% excluding Sentinel) excluding the unfavorable impact of exchange rates.

This very good third quarter performance reinforces the growth observed in the first half of the year, reflecting the resilience of the sector, and the constant mobilization of Virbac teams. These have allowed us to achieve growth in all regions (excluding the impact of the divestment of Sentinel), despite vaccine shortages. Europe and the Asia-Pacific region led the growth up until the end of September at +5.7% (+5.6% at constant exchange rates) and +4.0% (+7.8% at constant exchange rates) respectively, although some countries were more affected by the health crisis (United Kingdom and Italy). Latin America evolved by -1.8% (+9.3% at constant rates), carried by the dynamism of Brazil and Mexico over the period. Lastly, the United States achieved an evolution of -2.1% (-2.6% at constant rates and +4.5% excluding Sentinel), thanks in particular to sales of the dermatology and nutraceutical ranges, which compensated for the withdrawal of the dental and antibiotic ranges.

In terms of species, the companion animals business grew generally by +2.2% at actual rates (+3.6% at constant rates and +6.1% excluding Sentinel), essentially driven by growth in the specialty, pet food, dermatology and hygiene ranges, which compensated for the withdrawal of the vaccines and antibiotics ranges. The food-producing animals segment also recorded strong growth of +2.5% (+8.2% at constant rates), driven by the ruminant sector (+11.2% at constant rates) and the industrial farming sector (+3.0% at constant rates), while aquaculture fell slightly (-0.3% at constant rates) compared to the same period in 2019.

Outlook
The animal health sector has demonstrated strong resilience in recent months, which helped to limit the impact on our business at the end of September, and leads us to raise our outlook for the year. We are now anticipating revenue that might range between 0% and 3% for the year 2020 at actual scope (after the disposal of Sentinel) and at constant rates. Furthermore, we anticipate an unfavorable exchange rate impact on revenue of approximately €30 million related to the sharp depreciation of currencies in the Latin America and Asia-Pacific regions. The ‘current operating profit before depreciation of assets arising from acquisitions’ to ‘revenue’ ratio should benefit from the favorable impact of the activity mentioned above as well as the non-recurring impact related to the sharp reduction in expenditure. This means it should fall between 13% and 15% at actual scope and at constant rates for the year 2020.

Finally, the early July divestment of the Sentinel brands (for which we will continue to manufacture the Sentinel Spectrum formulation at our US site in Bridgeton), is expected to result in revenue decrease of approximately US$55 million and a decrease in the EBITA2 to revenue ratio of approximately 3 points on a pro forma full-year basis. Across 2020, the impact on the EBITA to revenue ratio should be limited to around 1 point, given good Sentinel sales, which represented revenue of US$39 million in the first half of the year.

From a financial standpoint, the divestment of Sentinel for a total of US$410 million resulted in negative net debt. Lines of credit drawn in US dollars were repaid, and most of our financing, which essentially matures in 2022, was retained to cover potential working capital requirements, external growth operations or other projects.


CONSOLIDATED DATA
Unaudited figures - 
in millions of euros
20202019GrowthGrowth 
at constant exchange rates1
Growth 
at constant exchange rates and scope1
Revenue for 1st quarter247.7217.5+13.9%+14.3%+14.3%
Revenue for 2nd quarter230.6246.2-6.4%-3.3%-3.3%
Revenue for 3rd quarter235.6233.5+0.9%+6.8%+11.1%
Revenue at the end of September713.9697.3+2.4%+5,6%+6.8%
Revenue excluding Sentinel676.6654.8+3.3%+6.8%+6.8%






2
EBITA: Current operating profit before depreciations of assets arising from acquisitions.

A lifelong commitment to animal health

Virbac offers veterinarians, farmers and pet owners in more than 100 countries a practical range of products and services for diagnosing, preventing and treating the majority of diseases while improving quality of life for animals. With these innovative solutions covering more than 50 species, Virbac contributes day after day to shaping the future of animal health.


Virbac : NYSE Euronext - compartiment A - code ISIN : FR0000031577 / MNEMO : VIRP
Direction financière : tél. +33 4 92 08 71 32 - finances@virbac.com - corporate.virbac.com

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Sinch AB (publ): Sinch announces the completion of a directed new share issue of 3,187,736 shares, raising approx. SEK 3.3 billion, and larger shareholders’ sale of existing shares to a fund managed by SB Management30.11.2020 23:58:07 CETPress release

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, NEW ZEALAND, HONG KONG, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE MAY BE UNLAWFUL, WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES Press Release Stockholm, 30 November 2020 Sinch announces the completion of a directed new share issue of 3,187,736 shares, raising approx. SEK 3.3 billion, and larger shareholders’ sale of existing shares to a fund managed by SB Management Stockholm, Sweden – Sinch AB (publ) – XSTO: SINCH Sinch AB (publ) (“Sinch” or the “Company”) has, in accordance with the Company’s press release earlier today on 30 November 2020 and based on the authorization granted by the annual general meeting on 15 May 2020, resolved on a directed issue of 3,187,736 new shares at a subscription price of SEK 1,050 per share (the “Share Issue”), corresponding to (i) a discount of a

Sinch AB (publ): Sinch offentliggör genomförandet av en riktad nyemission om 3 187 736 aktier och tillförs ca 3,3 miljarder kronor, samt större aktieägares försäljning av befintliga aktier till en fond förvaltad av SB Management30.11.2020 23:58:07 CETPressemelding

EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUERING ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, I ELLER TILL USA, KANADA, JAPAN, AUSTRALIEN, SYDAFRIKA, NYA ZEELAND, HONGKONG, SINGAPORE ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTIONEN ELLER PUBLICERING AV DETTA PRESSMEDDELANDE SKULLE KUNNA VARA OLAGLIG, KRÄVA YTTERLIGARE REGISTRERING ELLER ANDRA ÅTGÄRDER Pressmeddelande Stockholm den 30 november 2020 Sinch offentliggör genomförandet av en riktad nyemission om 3 187 736 aktier och tillförs ca 3,3 miljarder kronor, samt större aktieägares försäljning av befintliga aktier till en fond förvaltad av SB Management Stockholm, Sverige – Sinch AB (publ) – XSTO: SINCH Sinch AB (publ) (”Sinch” eller ”Bolaget”) har, i enlighet med Bolagets tidigare pressmeddelande idag den 30 november 2020 och med stöd av årsstämmans bemyndigande från den 15 maj 2020, beslutat om en riktad nyemission om 3 187 736 nya aktier till en teckningskurs om 1 050 kronor per aktie (”Nyemissionen”), motsvarande

Stop & Shop Local Unions Ratify Previously Announced Withdrawal Agreement on UFCW International Union - Industry Pension Fund; No Impact to Previously Issued Outlook30.11.2020 22:30:00 CETPress release

Zaandam, the Netherlands, November 30, 2020 – Ahold Delhaize announces today that the UFCW Locals of its U.S. brand Stop & Shop have ratified the agreement to terminate participation in the United Food & Commercial Workers International Union – Industry Pension Fund (the “National Plan”). As previously announced, the agreement does not impact the 2020 financial outlook. Details of the financial impact were outlined in the original release on July 21st, 2020, and can be found here. This withdrawal improves the security of pension benefits for associates as well as reduces financial risk for the company and was determined, by the National Plan’s trustees, to be in the best interests of the National Plan’s participants and beneficiaries. Also as previously announced, Stop & Shop, together with Kroger and the UFCW Locals, are creating the UFCW International Union-Industry Variable Annuity Pension Plan for future benefits. This new plan is designed to protect the benefit accrual of particip

Galapagos reports positive topline results with GLPG1205 in IPF patients in PINTA Proof-of-Concept trial30.11.2020 22:01:00 CETPress release

Placebo-adjusted improvement in forced vital capacity (FVC) decline of 42mL across treatment groups at 26 weeksCorrelation between FVC decline and pulmonary lobar volume change observed, as measured by functional respiratory imaging (FRI) GLPG1205 planned to progress to dose finding Phase 2b study Mechelen, Belgium; 30 November 2020, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announces positive topline results with its investigational GPR84 antagonist GLPG1205 in Proof-of-Concept Phase 2 trial in idiopathic pulmonary fibrosis (IPF) patients. The PINTA trial was a randomized, double-blind, placebo-controlled trial investigating a 100mg once-daily oral dose of GLPG1205. The study recruited and included a total of 68 IPF patients. Participants were administered drug candidate or placebo (2:1 randomization) for 26 weeks and could remain on their standard of care as background therapy, i.e. nintedanib, pirfenidone or neither. The primary objective of the trial was to assess the chang

AB Linas Agro Group performance and financial results for the three months of 2020/2130.11.2020 21:27:53 CETPress release

Consolidated revenue went up 60% to EUR 239 million. Sales volume in tons reached 769 thousand tons of various products and was 75% more as compared to previous year. The gross profit reached EUR 13.2 million and was 26% higher than a year before. Consolidated EBITDA was 92% higher and amounted to EUR 9.2 million. The operating profit was EUR 4.9 million or 260% higher. Profit before taxes amounted to EUR 4.5 million against EUR 0.9 million in previous year. The net profit attributable to the Company went up from EUR 0.6 million to EUR 3.9 million. A commentary by Mažvydas Šileika, Financial Director of AB Linas Agro Group: "A good harvest has helped to achieve very good trading results, and poultry business was the one most affected by the global pandemic. Revenue from trade in grain, oilseeds and feedstuff increased by 100% over the year to EUR 172 million, and operating profit amounted to EUR 3.3 million being 4.7 times higher. Due to the successful growing season, our customers-far

Millicom CEO Mauricio Ramos to be keynote speaker at GSMA Thrive Latin America30.11.2020 21:00:00 CETPress release

Millicom CEO Mauricio Ramos to be keynote speaker at GSMA Thrive Latin America Luxembourg, November 30, 2020 – Millicom, a leading provider of cable and mobile services operating as TIGO in Latin America, is pleased to announce that CEO Mauricio Ramos will present at GSMA Thrive Latin America as an invited keynote speaker on December 2. As a global leader in the telecommunications sector, Mr. Ramos will discuss the importance of accelerating connectivity to reinvigorate economies in Latin America and its positive effect on communities. GSMA Thrive Latin America brings together Latin America’s policymakers, digital leaders, and innovators to uncover the opportunities of emerging next-generation technologies and inspire thought leadership to solve the challenges of realizing a truly connected world. Mr. Ramos’s keynote presentation at GSMA Thrive Latin America is scheduled for Wednesday, December 2 at 10:00 a.m. ET. Free registration and the keynote can be accessed here [LINK]. -END- For